ResMed Inc. Announces CFO Transition and Appoints Aaron Bloomer as Successor

ResMed Inc. announced that Brett Sandercock, Chief Financial Officer, will retire effective May 4, 2026. He will transition to a Special Advisor role to the CEO through December 31, 2026, and then as a consultant through December 31, 2027, continuing to receive his salary and benefits, with continued vesting of equity incentives. Sandercock's retirement is not due to any disagreements with the company. Aaron Bloomer has been appointed as the new Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective May 4, 2026. Bloomer brings over 17 years of global finance and operating leadership experience, previously serving as CFO of Exact Sciences Corporation. His compensation package includes a base salary of $725,000, a $150,000 sign-on bonus, an 80% target annual incentive bonus, and a $3.3 million long-term equity grant. Bloomer will also receive relocation assistance and will be eligible for the company's executive severance and change in control arrangements. ResMed also reiterated its financial outlook for fiscal year 2026.